HOPHD
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, a… Read more
HOPHD (HOPHD) - Total Assets
Latest total assets as of December 2023: $6.11 Million USD
Based on the latest financial reports, HOPHD (HOPHD) holds total assets worth $6.11 Million USD as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HOPHD - Total Assets Trend (2020–2023)
This chart illustrates how HOPHD’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
HOPHD - Asset Composition Analysis
Current Asset Composition (December 2023)
HOPHD's total assets of $6.11 Million consist of 35.5% current assets and 64.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.4% |
| Accounts Receivable | $1.07K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $441.49K | 7.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how HOPHD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HOPHD's current assets represent 35.5% of total assets in 2023, a decrease from 72.0% in 2020.
- Cash Position: Cash and equivalents constituted 20.4% of total assets in 2023, down from 68.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 9.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 7.2% of total assets.
HOPHD Competitors by Total Assets
Key competitors of HOPHD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
HOPHD - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - HOPHD generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - HOPHD is currently not profitable relative to its asset base.
HOPHD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.33 | 4.07 | - |
| Quick Ratio | 3.33 | 4.07 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $1.52 Million | $ 2.39 Million | - |
HOPHD - Advanced Valuation Insights
This section examines the relationship between HOPHD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -13.9% |
| Total Assets | $6.11 Million |
| Market Capitalization | $11.96K USD |
Valuation Analysis
Below Book Valuation: The market values HOPHD's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: HOPHD's assets decreased by 13.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for HOPHD (2020–2023)
The table below shows the annual total assets of HOPHD from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $6.11 Million | -13.91% |
| 2022-12-31 | $7.09 Million | -16.76% |
| 2021-12-31 | $8.52 Million | +219.77% |
| 2020-12-31 | $2.66 Million | -- |